Scholarlink

Purpose <p>To describe real-world characteristics and clinical outcomes among patients with HER2+ MBC receiving tucatinib-based treatments.</p> Methods <p>This retrospective study included patients diagnosed with HER2+ MBC between January 2017 and December 2022 from two administrative health claims databases, Merative<sup>TM</sup>MarketScan<sup>®</sup> and the Komodo Healthcare Map<sup>™</sup>. Patient characteristics were captured at baseline (≤ 6&#xa0;months prior to tucatinib initiation). Outcomes were assessed starting from tucatinib-based treatment initiation and included real-world time to discontinuation (rwTTD) and treatment persistence.</p> Results <p>There were 150 patients in MarketScan<sup>®</sup> who received tucatinib-based therapy: median (IQR) prior lines of therapy (LOT) was 2 (2–4) and 110 patients (73.3%) had brain metastases. 436 patients in Komodo<sup>™</sup> received tucatinib-based therapy: median (IQR) prior LOTs were 2 (1–3), and 307 (70.4%) had brain metastases. Median (95% CI) rwTTD was 7.4 (5.0–13.1) months in MarketScan<sup>®</sup> (median follow-up 9.7&#xa0;months) and 9.0 (7.4–9.8) months in Komodo<sup>™</sup> (median follow-up 10.3&#xa0;months). In patients who received tucatinib in combination with trastuzumab and capecitabine immediately following trastuzumab deruxtecan (T-DXd) and after ≥ 2 prior HER2-directed therapies (MarketScan<sup>®</sup>: n = 26, median prior LOT 4; Komodo: <i>n</i> = 34, median prior LOT 3), median (95% CI) rwTTD was 5.5 (3.4–not reached [NR]) months in MarketScan<sup>®</sup> and 4.8 (3.2–NR) months in Komodo.</p> Conclusion <p>These results reinforce the real-world effectiveness of tucatinib in patients with HER2+ MBC, including patients with prior T-DXd treatment. Further research is needed to determine the optimal treatment sequencing for patients with HER2+ MBC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月6日

查看全文
  • Carey Anders,
  • Edward Neuberger,
  • Naomi R. M. Schwartz,
  • Karen Bartley,
  • Shu Wang,
  • Yutong Liu,
  • Brian T. Pittner,
  • Peter A. Kaufman,
  • Jane Meisel

摘要

Purpose

To describe real-world characteristics and clinical outcomes among patients with HER2+ MBC receiving tucatinib-based treatments.

Methods

This retrospective study included patients diagnosed with HER2+ MBC between January 2017 and December 2022 from two administrative health claims databases, MerativeTMMarketScan® and the Komodo Healthcare Map™. Patient characteristics were captured at baseline (≤ 6 months prior to tucatinib initiation). Outcomes were assessed starting from tucatinib-based treatment initiation and included real-world time to discontinuation (rwTTD) and treatment persistence.

Results

There were 150 patients in MarketScan® who received tucatinib-based therapy: median (IQR) prior lines of therapy (LOT) was 2 (2–4) and 110 patients (73.3%) had brain metastases. 436 patients in Komodo™ received tucatinib-based therapy: median (IQR) prior LOTs were 2 (1–3), and 307 (70.4%) had brain metastases. Median (95% CI) rwTTD was 7.4 (5.0–13.1) months in MarketScan® (median follow-up 9.7 months) and 9.0 (7.4–9.8) months in Komodo™ (median follow-up 10.3 months). In patients who received tucatinib in combination with trastuzumab and capecitabine immediately following trastuzumab deruxtecan (T-DXd) and after ≥ 2 prior HER2-directed therapies (MarketScan®: n = 26, median prior LOT 4; Komodo: n = 34, median prior LOT 3), median (95% CI) rwTTD was 5.5 (3.4–not reached [NR]) months in MarketScan® and 4.8 (3.2–NR) months in Komodo.

Conclusion

These results reinforce the real-world effectiveness of tucatinib in patients with HER2+ MBC, including patients with prior T-DXd treatment. Further research is needed to determine the optimal treatment sequencing for patients with HER2+ MBC.